Ocugen, Inc.
As of Oct 22, 2026, Ocugen is in Stage 4, the downtrend phase, now in week 6 (since Sep 14, 2026). It closed at $0.79, 68.1% below its 52-week high and below its 200-day average, which is falling.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is OCGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
OCGN among Biotechnology347th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …347 | OCGN | Stage 4 · wk 6 | 24 | −21.0% |
Ocugen: quick answers
What stage is Ocugen in?
As of Oct 22, 2026, Ocugen (OCGN) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Ocugen in an uptrend?
No. Ocugen is in a Stage 4 downtrend. It trades 45.8% below its 200-day average, which is falling.
How far is Ocugen from its 52-week high?
Ocugen closed at $0.79 on Oct 22, 2026, 68.1% below its 52-week high of $2.48. Its 52-week low is $0.78.
How has Ocugen performed over the past year?
As of Oct 22, 2026, Ocugen is down 49.7% over the past year and down 42.8% so far in 2026.
Which sector and industry is Ocugen in?
Ocugen is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.